The application of neoadjuvant chemotherapy oxaliplatin plus capecitabine in mid-low rectal carcinoma

Mengmeng Jiang,Zhengrong Li,Yi Cao,Zhigang Jie
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2014.24.008
2014-01-01
Abstract:Objective To explore the clinical efficacy of neoadjuvant chemotherapy oxaliplatin plus capecitabine (XELOX) in middle-low rectal carcinoma. Methods Between February 2012 and February 2014, 112 patients with middle-low rectal carcinoma at our hospital, no evidence of distant metastases, were included in this study, which were divided into the experimental group (56 cases) and control group (56 cases). Patients in the experimental group were respectively treated with two cycles XELOX regimen (oxaliplatin 130 mg/m2 on day 1 with capecitabine 400 mg/m2 twice daily for 14 days every 3 weeks), patients in the control group were not given any chemoradiation. Tumor response, toxicities, and surgical complications were recorded. Results The experimental group with tumor size became smaller, more soft, tissue space became more wide, was exhibited in 55.357% (31/56). The anal sphincter preservation rate in the experimental group was significantly higher than in control group (P<0.05), the rate of lymph node metastasis in the experimental group was significantly lower than in the control group (P<0.05). Anastomotic leakage rate had significant difference (P<0.05). Conclusion Neoadjuvant oxaliplatin plus capecitabine in the treatment of patients with middle-low rectal carcinoma, can significantly improve the rate of anal preservation, the rate of lymph node metastasis was significantly lower, the incidence of anastomotic fistula did not increase.
What problem does this paper attempt to address?